GlassScriptPhysician profile
John P Tucker
NPI 1457347130
$1,390.44
in general payments reported to CMS, 2019-2025
17 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.83 · 2020: $214 · 2021: $226 · 2022: $339 · 2023: $289 · 2024: $79.90 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $287.97 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $266.85 | 2021-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $214.47 | 2020-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $73.72 | 2019-2025 | Breztri |
| Pfizer INC. | $73.54 | 2019-2024 | |
| Abbott Laboratories | $73.10 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $68.56 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $66.08 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Smith+Nephew, INC. | $52.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $52.12 | 2021-2022 | |
| Dexcom, INC. | $40.69 | 2022-2025 | Dexcom G6 Transmitter |
| Blueprint Medicines Corporation | $39.66 | 2021-2022 | |
| Halozyme INC | $21.27 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.81 | 2022 | |
| Exact Sciences Corporation | $15.40 | 2023 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $13.06 | 2023 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.